New Alzheimer's Drug Approval Expands Treatment Options — and Creates Coverage Questions

This episode is brought to you by Semafor Healthcare.

Delivered weekly from David Lim, Semafor Healthcare connects the dots between decisions in government, business, and technology to reveal how they impact the future of healthcare. Each edition will provide the analysis you need to understand and stay ahead of a rapidly changing landscape. Subscribe for free.

Health Affairs' Jeff Byers welcomes Senior Editor Leslie Erdelack to the program to discuss FDA's recent approval of an Alzheimer's treatment drug, Lilly’s Kisunla, how private insurers and Medicare may cover the drug, and the emerging new class of drugs surrounding Alzheimer's treatment.

We announced the winner for our You're A Health Policy Wonk If... contest this week!

Until July 20, we are having a flash sale on Health Affairs Insider membership. Use the code HealthWonkLife for $30 off the normal Insider price.

Check out our Request For Abstracts page for the April 2025 theme issue focusing on Food, Nutrition, and Health.

Related Articles:

• Approval of Newest Alzheimer’s Drug Will Accelerate New Era of Treatment by Peter Loftus and Joseph Walker (Wall Street Journal)
• Press Release: Lilly's Kisunla Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease

Subscribe to Semafor Healthcare for free.